251 286 - Biotech Bayern

Contact:
Dr. Klaus-Peter Stengele
Beuthenerstr. 2
D-84478 Waldkraiburg
Phone: +49 (0) 8638 98420
Fax: +49 (0) 8638 984211
E-Mail: stengele@nimblegen.de
Internet: www.nimblegen.de
Contact:
Martin Bischof
Zielstattstr. 40
D-81379 München
Phone: +49 (0) 89 7877-0
Fax: +49 (0) 89 7877-250
E-Mail:
communications.munich de@novartis.com
Internet: www.novartis-consumerhealth.de
Contact:
Astrid Oelsner
Am Klopferspitz 19
D-82152 Martinsried
Phone: +49 (0) 89 700 769-60
Fax: +49 (0) 89 700 769-61
E-Mail: info@octagene.com
Internet: www.octagene.com
90
NimbleGen Systems GmbH
BIOTECH DEVICES & REAGENTS
Keywords: Clinical Diagnostics, Fine Chemicals / Reagents,
Chip / Array Technology, Genomics
NimbleGen Systems, the leading supplier of flexible high-density microarray
products and services, is enabling a new era of High-Definition Genomics (SM).
NimbleGen uniquely produces high-density arrays of isothermal long oligos that
provide superior results for advanced genomic analysis methods such as CGH,
ChIP, microbial Comparative Genome Sequencing, and expression tiling.
NimbleGen's High-Definition Genomics enables scientists to obtain and integrate
complex genomic data sets not previously accessible, providing a much
clearer understanding of genome structure and function, and how this relates to
biology and medicine. NimbleGen Systems GmbH is the wholly owned German
subsidiary of Nimblegen Systems Inc and the chemistry arm of NimbleGen.
Novartis Consumer Health GmbH
PHARMA & CHEMICAL INDUSTRY
Novartis Consumer Health, located in Munich, merchandises and distributes
OTC and prescription drugs for self-medication.
OCTAGENE GmbH
BIOTECH THERAPEUTICS & DIAGNOSTICS
Drug Development, Hematology, Peptide/Protein
Octagene GmbH is a product-oriented R&D company with 25 employees located
in Martinsried. The main focus of Octagene is the development of cell lines for
production of recombinant proteins.
Using a High-Throughput Screening Technology for optimized clone selection,
Octagene has achieved a significant increase in efficiency and productivity of
the cell clones. This technology is offered as service to other companies. The use
of human cells as host cells has substantially improved the compatibility of
Octagenes final drug product in patients in comparison to hamster cell-derived
products. One product developed by Octagene, recombinant human Factor VIII,
will soon enter clinical phase II.